{
  "source": "PA-Notification-Zurzuvae.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1424-2\nProgram Prior Authorization/Notification\nMedication Zurzuvae® (zuranolone)\nP&T Approval Date 12/2023, 12/2024\nEffective Date 3/1/2025\n1. Background:\nZurzuvae is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive\nmodulator indicated for the treatment of postpartum depression (PPD) in adults.\n2. Coverage Criteriaa:\nA. Authorization\n1. Zurzuvae will be approved based on both of the following criteria:\na. Diagnosis of postpartum depression (PPD)\n-AND-\nb. Onset of current depressive episode was during the third trimester or within 4 weeks\npostpartum\nAuthorization will be issued for 1 month.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class\n• Supply limits may be in place.\n4. References:\n1. Zurzuvae [package insert]. Cambridge, MA; Biogen Inc.; July 2024.\n© 2024 UnitedHealthcare Services, Inc.\n1\nProgram Prior Authorization/Notification – Zurzuvae (zuranolone)\nChange Control\n12/2023 New program.\n12/2024 Annual review without changes to clinical criteria. Updated reference.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}